Related Experiment Video

Updated: Jul 3, 2025

Construction and Evaluation of a Murine Calvarial Osteolysis Model by Exposure to CoCrMo Particles in Aseptic Loosening
09:46

Construction and Evaluation of a Murine Calvarial Osteolysis Model by Exposure to CoCrMo Particles in Aseptic Loosening

Published on: February 17, 2018

7.9K

Inhibitory effects of norcantharidin on titanium particle-induced osteolysis, osteoclast activation and bone

Jing Wang1, Gang Chen1, Xue Yang1

  • 1Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China.

International Immunopharmacology
|February 10, 2024
PubMed

Insights

Norcantharidin (NCTD) effectively inhibits osteoclast formation and bone resorption, offering a potential treatment for aseptic loosening caused by implant wear particles. This study highlights NCTD

Area of Science:

  • Biomedical Engineering
  • Orthopedics
  • Pharmacology

Background:

  • Peri-implant osteolysis and aseptic loosening are major complications following joint arthroplasty, driven by wear particles and osteoclast activity.
  • Current treatments for particle-induced bone resorption have limitations and significant side effects.
  • There is a critical need for novel therapeutic agents with improved efficacy and safety profiles.

Purpose of the Study:

  • To investigate the potential of Norcantharidin (NCTD), a known anti-tumor agent, in treating aseptic loosening of prostheses.
  • To evaluate NCTD's effects on osteoclast formation, bone resorption, and associated molecular pathways in vitro and in vivo.

Main Methods:

  • In vitro studies assessed NCTD's impact on receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis and bone resorption.
  • Key molecular targets, including c-Fos, NFATc1, and osteoclast-specific genes (TRAP, CTR, CTSK), were analyzed.
  • In vivo experiments evaluated NCTD's efficacy against titanium particle-induced osteolysis and inflammation, examining MAPK signaling pathways.

Main Results:

  • NCTD significantly inhibited RANKL-induced osteoclast formation and bone resorption in vitro.
  • NCTD suppressed the expression of critical osteoclastogenic transcription factors (c-Fos, NFATc1) and specific genes.
  • In vivo, NCTD demonstrated protective effects against particle-induced osteolysis and inflammation by inhibiting MAPK signaling.

Conclusions:

  • NCTD shows significant potential as a therapeutic agent for aseptic loosening following total joint arthroplasty.
  • NCTD's mechanism involves the inhibition of osteoclastogenesis and related inflammatory signaling pathways.
  • Further research into NCTD could lead to improved treatments for implant-related bone loss.
Keywords:
Bone resorptionInflammationMAPK signaling pathwayNorcantharidinOsteoclast formationOsteolysis

More Related Videos

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

6.1K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.2K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K